Literature DB >> 25908322

Peak ages of risk for starting nonmedical use of prescription stimulants.

E A Austic1, E A Austic Formerly E A Meier.   

Abstract

BACKGROUND: To produce population-level, year- and age-specific risk estimates of first time nonmedical use of prescription stimulants among young people in the United States.
METHODS: Data are from the National Surveys on Drug Use and Health 2004-2012; a nationally representative probability sample survey administered each year. Subpopulations included youths aged 12 to 21 years (n=240,160) who had not used prescription stimulants nonmedically prior to their year of survey assessment. A meta-analytic approach was used to produce population-level age-, year-, and cohort-specific risk estimates of first time nonmedical use of prescription stimulants.
RESULTS: Peak risk of starting nonmedical use of prescription stimulants was concentrated between ages 16 and 19 years, when an estimated 0.7% to 0.8% of young people reported nonmedical use of these medicines for the first time in the past twelve months. Smaller risk estimates ranging from 0.1% to 0.6% were observed at ages 12 to 15 years and 20 to 21 years. Compared with males, females were more likely to have started nonmedical use of prescription stimulants (odds ratio=1.35; 95% CI, 1.13-1.62), particularly between the ages of 14 and 19. Females showed a peak annual incidence rate of 1% at age 18, while males the same age showed an incidence rate of 0.5%.
CONCLUSIONS: Peak annual incidence rates for nonmedical use of prescription stimulants were observed between the ages of 16 and 19 years. There is reason to initiate interventions during the earlier adolescent years to prevent youths from starting nonmedical use of prescription stimulants.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adolescent; Nonmedical use; Stimulant

Mesh:

Substances:

Year:  2015        PMID: 25908322      PMCID: PMC4458195          DOI: 10.1016/j.drugalcdep.2015.03.034

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  15 in total

1.  Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study.

Authors:  Russell A Barkley; Mariellen Fischer; Lori Smallish; Kenneth Fletcher
Journal:  Pediatrics       Date:  2003-01       Impact factor: 7.124

2.  Medical use, illicit use and diversion of prescription stimulant medication.

Authors:  Sean Esteban McCabe; Christian J Teter; Carol J Boyd
Journal:  J Psychoactive Drugs       Date:  2006-03

3.  Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.

Authors:  J Biederman; T Wilens; E Mick; T Spencer; S V Faraone
Journal:  Pediatrics       Date:  1999-08       Impact factor: 7.124

4.  Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study.

Authors:  Slavica K Katusic; William J Barbaresi; Robert C Colligan; Amy L Weaver; Cynthia L Leibson; Steven J Jacobsen
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-10       Impact factor: 2.576

5.  Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood.

Authors:  Salvatore Mannuzza; Rachel G Klein; Nhan L Truong; John L Moulton; Erica R Roizen; Kathryn H Howell; Francisco X Castellanos
Journal:  Am J Psychiatry       Date:  2008-04-01       Impact factor: 18.112

6.  Medical and nonmedical use of prescription stimulants: results from a national multicohort study.

Authors:  Sean Esteban McCabe; Brady T West
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-09-23       Impact factor: 8.829

7.  Prevalence of illicit use and abuse of prescription stimulants, alcohol, and other drugs among college students: relationship with age at initiation of prescription stimulants.

Authors:  Kristy B Kaloyanides; Sean E McCabe; James A Cranford; Christian J Teter
Journal:  Pharmacotherapy       Date:  2007-05       Impact factor: 4.705

8.  Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011.

Authors:  Susanna N Visser; Melissa L Danielson; Rebecca H Bitsko; Joseph R Holbrook; Michael D Kogan; Reem M Ghandour; Ruth Perou; Stephen J Blumberg
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-11-21       Impact factor: 8.829

Review 9.  Early-onset drug use and risk for drug dependence problems.

Authors:  Chuan-Yu Chen; Carla L Storr; James C Anthony
Journal:  Addict Behav       Date:  2008-11-01       Impact factor: 3.913

10.  Coming to terms with the nonmedical use of prescription medications.

Authors:  Carol J Boyd; Sean E McCabe
Journal:  Subst Abuse Treat Prev Policy       Date:  2008-11-18
View more
  7 in total

1.  International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.

Authors:  Cleo L Crunelle; Wim van den Brink; Franz Moggi; Maija Konstenius; Johan Franck; Frances R Levin; Geurt van de Glind; Zsolt Demetrovics; Corné Coetzee; Mathias Luderer; Arnt Schellekens; Frieda Matthys
Journal:  Eur Addict Res       Date:  2018-03-06       Impact factor: 3.015

2.  Investigating sex differences and the effect of drug exposure order in the sensory reward-enhancing effects of nicotine and d-amphetamine alone and in combination.

Authors:  Kathleen R McNealy; Sydney D Houser; Scott T Barrett; Rick A Bevins
Journal:  Neuropharmacology       Date:  2021-10-19       Impact factor: 5.250

Review 3.  Prescription stimulant medication misuse: Where are we and where do we go from here?

Authors:  Lisa L Weyandt; Danielle R Oster; Marisa E Marraccini; Bergljot Gyda Gudmundsdottir; Bailey A Munro; Emma S Rathkey; Alison McCallum
Journal:  Exp Clin Psychopharmacol       Date:  2016-10       Impact factor: 3.157

4.  Developmental course of non-medical use of prescription drugs from adolescence to adulthood in the United States: national longitudinal data.

Authors:  Sean Esteban McCabe; Deborah D Kloska; Philip Veliz; Justin Jager; John E Schulenberg
Journal:  Addiction       Date:  2016-08-09       Impact factor: 6.526

5.  Alcohol-related cognitions: Implications for concurrent alcohol and marijuana use and concurrent alcohol and prescription stimulant misuse among young adults.

Authors:  Dana M Litt; Ashley Lowery; Cassidy LoParco; Melissa A Lewis
Journal:  Addict Behav       Date:  2021-04-06       Impact factor: 4.591

Review 6.  Addressing adolescent substance use with a public health prevention framework: the case for harm reduction.

Authors:  James Michael Winer; Amy M Yule; Scott E Hadland; Sarah M Bagley
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

Review 7.  Prescription Drug Misuse: Taking a Lifespan Perspective.

Authors:  Ty S Schepis; Dalton L Klare; Jason A Ford; Sean Esteban McCabe
Journal:  Subst Abuse       Date:  2020-03-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.